Mirum Pharmaceuticals (STU:08D) Operating Margin %: -39.51% (As of Mar. 2026)


STU:08D Mirum Pharmaceuticals Inc STU:08D
47 GF Score
Price €97.60
GF Value €72.26
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Mirum Pharmaceuticals Operating Margin %?

Mirum Pharmaceuticals STU:08D +3.59% 47 Operating Margin % is -39.51% as of Mar. 2026. GuruFocus rates STU:08D with a GF Score™ of 47/100 and a GF Value™ of €72.26 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 945 Biotechnology companies, Mirum Pharmaceuticals ranks better than 65.19% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Mirum Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was €-54.6 Mil. Mirum Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was €138.3 Mil. Therefore, Mirum Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2026 was -39.51%.

The historical rank and industry rank for Mirum Pharmaceuticals's Operating Margin % or its related term are showing as below:

STU:08D' s Operating Margin % Range Over the Past 10 Years
Min: -906.12   Med: -58.57   Max: -4.25
Current: -12.31


STU:08D's Operating Margin % is ranked better than
65.19% of 945 companies
in the Biotechnology industry
Industry Median: -86.77 vs STU:08D: -12.31

Mirum Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Mirum Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was €-54.6 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was €-60.6 Mil.


Mirum Pharmaceuticals  (STU:08D) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Mirum Pharmaceuticals Operating Margin % Related Terms


Mirum Pharmaceuticals Operating Margin % Historical Data

* Premium members only.

The historical data trend for Mirum Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mirum Pharmaceuticals Operating Margin % Chart

Mirum Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial -906.13 -170.28 -58.57 -26.00 -4.25

Mirum Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.13 -3.90 1.96 -3.07 -39.51

STU:08D vs APGE, PTCT, RYTM: Operating Margin % Comparison

For the Biotechnology subindustry, Mirum Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mirum Pharmaceuticals Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Mirum Pharmaceuticals's Operating Margin % falls into.


STU:08D
47GF Score
Mirum Pharmaceuticals Inc STU:08D
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mirum Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Mirum Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-18.904 / 445.2
=-4.25 %

Mirum Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-54.636 / 138.298
=-39.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -39.51% mean?
Mirum Pharmaceuticals (STU:08D) has a Operating Margin % of -39.51% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Mirum Pharmaceuticals and its competitors. According to the industry distribution chart, Mirum Pharmaceuticals ranks #329 out of 945 companies in the Biotechnology industry, placing it in the top 34.8%.
Is Mirum Pharmaceuticals' Operating Margin % too high?
Mirum Pharmaceuticals' current Operating Margin % is -39.51%. Based on the distribution chart, Mirum Pharmaceuticals ranks #329 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Mirum Pharmaceuticals has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' Operating Margin % compare to APGE and PTCT?
According to the Biotechnology industry distribution chart, Mirum Pharmaceuticals ranks #329 out of 945 companies for Operating Margin %. This puts Mirum Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Mirum Pharmaceuticals and its competitors. Mirum Pharmaceuticals's current Operating Margin % is -39.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Mirum Pharmaceuticals (STU:08D) is currently considered Significantly Overvalued. The stock's GF Value™ is €72.26, compared to a current price of €97.60 — trading 35.1% above its estimated fair value. The current Operating Margin % is -39.51%. Mirum Pharmaceuticals' overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Mirum Pharmaceuticals (STU:08D), the current Operating Margin % is -39.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mirum Pharmaceuticals (STU:08D) Overvalued in 2026?

Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued. The current stock price of €97.60 is trading 35.1% above its estimated GF Value™ of €72.26. GuruFocus considers Mirum Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:08D:

  • Operating Margin %: -39.51%
  • GF Value™: €72.26 vs. price of €97.60 (35.1% above fair value)
  • GF Score™: 47/100 with 6 warning signs

No single metric tells the full story. See the STU:08D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mirum Pharmaceuticals Business Description

Other Exchanges MIRM:USA
Address 989 East Hillsdale Boulevard, Suite 300, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
47GF Score

Get the complete analysis for STU:08D

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€97.60
Price
€72.26
GF Value